MIRA Pharmaceuticals, Inc.
MIRA
$0.96
-$0.01-1.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 86.16% | -13.51% | -26.02% | -24.57% | -32.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.86% | -17.72% | -18.99% | -10.05% | -5.96% |
| Operating Income | -30.86% | 17.72% | 18.99% | 10.05% | 5.96% |
| Income Before Tax | -32.98% | 38.98% | 39.26% | 35.93% | 34.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.98% | 38.98% | 39.26% | 35.93% | 34.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.98% | 38.98% | 39.26% | 35.93% | 34.46% |
| EBIT | -30.86% | 17.72% | 18.99% | 10.05% | 5.96% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -197.73% | -100.61% | 45.98% | 42.01% | 38.06% |
| Normalized Basic EPS | 20.31% | 45.78% | 45.95% | 41.99% | 38.05% |
| EPS Diluted | -197.73% | -100.61% | 45.98% | 42.01% | 38.06% |
| Normalized Diluted EPS | 20.31% | 45.78% | 45.95% | 41.99% | 38.05% |
| Average Basic Shares Outstanding | 53.17% | 16.92% | 12.56% | 11.58% | 2.88% |
| Average Diluted Shares Outstanding | 53.17% | 16.92% | 12.56% | 11.58% | 2.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |